NCT03433391
Completed
Not Applicable
Confirmatory Clinical Study to Support the Effectiveness and Safety of Oxiplex for the Reduction of Pain and Symptoms Following Lumbar Surgery
FzioMed17 sites in 1 country135 target enrollmentApril 23, 2018
ConditionsHerniated Lumbar Disk
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Herniated Lumbar Disk
- Sponsor
- FzioMed
- Enrollment
- 135
- Locations
- 17
- Primary Endpoint
- Change in ipsilateral leg pain
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded clinical study to assess the safety and effectiveness for the reduction of pain and symptoms following lumbar surgery.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Be between 22 and 70 years of age;
- •Have symptomatic posterior or posterolateral disc herniation at L4-L5 or L5-S1 with radiographic confirmation of nerve compression using MRI that requires partial surgical discectomy with or without laminotomy;
- •Have radiculopathy (e.g., decreased motor strength, sensory deficits, decreased reflexes) from specific nerve root distribution from L4 to S1 with positive straight leg raise (0-60 degrees);
- •Have at least one of the following:
- •At least six weeks of prior conservative treatment (e.g., physical therapy and/or use of anti-inflammatory medications, narcotics, and muscle relaxants at the manufacturer's recommended therapeutic dose);
- •The patient is experiencing intractable pain; or
- •There is substantial progression of loss of neurological function.
- •Have VAS leg pain score in the ipsilateral leg of at least 60mm on a 100mm scale;
- •Have VAS back pain score of at least 50mm on a 100mm scale;
- •Be appropriate for treatment using a posterior surgical approach;
Exclusion Criteria
- •Pre-Operative Exclusion Criteria:
- •Radiographic confirmation (via MRI) of severe facet disease or facet degeneration at the index lumbar level;
- •Prior spine surgery at any lumbar level;
- •Subject requires spinal surgery other than a partial discectomy (with or without laminotomy) to treat leg/back pain (osteophyte removal is allowed);
- •Previous trauma to the lumbar spine resulting in fracture or documented ligament injury;
- •Documented presence of a free nuclear fragment at lumbar levels other than the study level;
- •Axial back pain only (no radicular symptoms);
- •Recent history (within previous six months) of chemical or alcohol dependence;
- •Active systemic infection;
- •Infection at the site of surgery;
Outcomes
Primary Outcomes
Change in ipsilateral leg pain
Time Frame: Pre-op; 6 weeks; 3 months; 6 months
Subjects will complete a Visual Analogue Scale (VAS) for their ipsilateral leg pain at each visit. The VAS is a continuous and linear, scale ranging from "No Pain" to "Worst Possible Pain".
Secondary Outcomes
- Change in back pain(Pre-op; 6 weeks; 3 months; 6 months)
Study Sites (17)
Loading locations...
Similar Trials
Completed
Phase 1
A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation FailureInfertility Implantation FailureNCT00504608Merck KGaA, Darmstadt, Germany150
Completed
Not Applicable
A Study of the Feasibility of Using the Dietary Supplement "ARTNEO" in Patients With OsteoathritisOsteoarthritis, KneeOsteoarthritisKnee OsteoarthritisKnee ArthritisKnee DiscomfortKnee Pain SwellingKnee Pain ChronicNCT05975879NPO Petrovax212
Not yet recruiting
Not Applicable
Clinical Study on the Noninvasive Lung Fluid Monitoring System in Guiding the Treatment of Heart FailureHeart FailureNCT06102031Shanghai Zhongshan Hospital1,000
Completed
Phase 3
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT02065557AbbVie101
Terminated
Phase 3
Tepilta® Versus Oxetacaine, Antacids and PlaceboRadiation-induced OesophagitisNCT01336530MEDA Pharma GmbH & Co. KG40